Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights
PR Newswire —
- Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications - - Interim Ph2 data readouts on track: SURF302 expected by end of 1H'26 and BEACH301 in 2H '26 - - Cash, cash equivalents and marketable...